Respiratory syncytial virus (RSV) belongs to Paramyxoviridae family of enveloped negative-strand RNA viruses and causes severe bronchiolitis and pneumonia in children younger than 2 years of age. As members of Paramyxoviridae family, RSV and parainfluenza type 3 (PIV3) have similar modes of infection and replication. A variety of negative-strand RNA virus infections, including that of PIV3, are inhibited by human MxA protein, a type I interferon (IFN)-inducible GTPase. We tested whether the MxA protein, induced either by type I human IFNs or by stable transfection of human MxA gene in human (U-87) or simian (Vero) cells, confers resistance to these cells against infection by RSV strain A2. RSV infection was resistant to antiviral effects induced by 0-10,000 U/ml type I IFNs (IFN-␣ or -␤) in both human lung epithelial, A549, and fibroblast, MRC-5 cells. RSV virus yield was reduced only by 10-to 20-fold, and viral protein synthesis was not significantly affected under conditions of IFN treatment where PIV3 yield was reduced by 1000-to 10,000-fold. Human or simian cell lines constitutively expressing MxA were protected against infection by PIV3 but not by RSV. Our results indicate that RSV A2 is resistant to the antiviral effects of MxA, even though RSV and PIV3 have similar replication strategies. In IFN-treated coinfected cultures, IFNresistant RSV A2 did not prevent the IFN-mediated inhibition of PIV3 multiplication. Hence the resistance of RSV A2 to type I IFNs does not appear to be due to soluble factors released into the medium or a disruption in the cellular antiviral machinery brought about by RSV A2 infection.
INTRODUCTION
Interferons (IFNs) are a heterogeneous family of cytokines with demonstrated antiviral, antitumor, and immunomodulatory activities (Pestka et al., 1987) . Their antiviral action is initiated via binding to species-specific cell surface receptors resulting in activation of IFN-stimulated genes (ISGs) and induction of a variety of intracellular proteins that inhibit viral replication via distinct mechanisms (Staeheli, 1990; Samuel, 1991; Anderson et al., 1999) . A subset of the IFN-induced intracellular proteins, the Mx proteins, are responsible for antiviral activities against a number of negative-strand RNA viruses. The murine nuclear Mx1 protein was shown to selectively block influenza virus replication (Pavlovic et al., 1990; Staeheli et al., 1986) , the rat Mx1 protein strongly inhibited both influenza virus and vesicular stomatitis virus (VSV), and rat Mx2 inhibited only VSV without affecting influenza virus replication (Meier et al., 1990) .
Human MxA is a 76-kDa protein that is induced to high levels in the cytoplasm of type I IFN-treated human cells and was shown to have potent GTPase activity (Horisberger et al., 1990; Horisberger, 1992; Pitossi et al., 1993) .
Constitutive expression of human MxA in Swiss 3T3 cells protected these cells against challenge with influenza A, VSV, and Thogoto virus (Staeheli et al., 1986; Haller, 1993; Haller et al., 1995) . Similarly, constitutive expression of human MxA inhibited replication of measles virus in the human monocytic cell line U937 (Schnorr et al., 1993) and in U-87 glioblastoma cells (Schneider-Schaulies et al., 1994) . MxA expression in U-87 cells also inhibited the replication of human parainfluenza type 3 (PIV3) (Zhao et al., 1996) . Likewise, expression of MxA in Vero cells inhibited virus replication and infectious virus yields of Hunta, Bunya, and Phlebo viruses (Kanerva et al., 1996; Frese et al., 1996) . Based on these studies, it was generally accepted that Mx proteins exhibit antiviral activity against negative-strand RNA viruses but not against picornaviruses with positive-strand RNA genome (Pavlovic et al., 1990) . However, a recent report indicates that Semliki forest virus (SFV), a Togavirus with a positivestrand RNA genome, was also inhibited by MxA protein expressed in Hep-2 cells (Landis et al., 1998) .
Respiratory syncytial virus (RSV) is the most important cause of severe bronchiolitis and pneumonia in infants and children younger than 2 years. RSV infection could be life threatening in children with certain predisposing conditions (Collins et al., 1996) . At present, there is no licensed vaccine against RSV infection. It is estimated that 100,000 hospitalizations and 4500 deaths occur an-nually in the United States due to RSV infections (MMWR, 1998) . In the absence of an effective vaccine for RSV, alternative treatments are being actively pursued (e.g., polyclonal antibodies, monoclonal antibodies, antisense nucleotides, and viral inhibitors). IFNs and other cytokines that augment intrinsic defenses of the lung against RSV would be of potential clinical benefit if the correct IFN subtypes, doses, and delivery routes needed for effective treatment were known.
The role of IFNs in RSV pathogenesis is controversial; some laboratory strains of RSV were reported to be acutely sensitive to either nonviral IFN-inducers such as poly(IC) or relatively impure preparations of IFNs (Hill et al., 1969; Gardner et al., 1970) . In contrast, during natural infection of children with RSV, very little or no IFN was detected in nasal washes, suggesting that IFNs may not have a role in curbing RSV replication at the site of infection (Moehring et al., 1971; Hall et al., 1978 Hall et al., , 1981 McIntosh, 1978) . Although some in vitro studies reported IFN production by RSV-infected peripheral blood monocytes and in macrophages, others reported a lack of IFN production in the same cells (Bell et al., 1983; Krilov et al., 1987; Roberts et al., 1992) . One study reported that IFN treatment of RSV-infected children does improve their clinical course, suggesting that exogenous IFN may augment intrinsic lung defense against this virus (Sung et al., 1993) . In clinical trials with adult volunteers, recombinant IFN-2␣ was not proved to be very successful as a therapeutic agent against RSV, strain RSS-2 (Higgins et al., 1990) . It is not known whether this particular IFN can, in fact, effectively decrease the replication and virus yield of this specific RSV strain in vitro. As is true with other viruses, different strains of RSV may have different degrees of sensitivity against a given type of IFN. Nevertheless, the apparent lack of clinical success of IFN as a therapeutic agent against RSV has dampened interest in using cellular antiviral responses to combat RSV infections. Many viruses have developed mechanisms to subvert early responses of the cellular IFN-mediated antiviral system (Smith, 1996; Krajcsi and Wold, 1998) . The role of RSV, if any, in counteracting early host defenses is unknown. PIV3 is sensitive to the antiviral effects of MxA protein, either induced by exogenously added IFN-␣ or expressed in permanently transfected cells (Zhao et al., 1996) .
In the present study, we compared the antiviral effects of human type I IFNs (␣ or ␤) and IFN inducers [poly(IC)] on replication of RSV strain A2 and PIV3 in either human lung epithelial cells (A549) or fibroblast cells (MRC-5). These two cell types were selected because RSV infects the lung epithelial lining and fibroblasts and hence may possess intrinsic mechanisms to restrict RSV replication (by induction of antiviral cytokines and IFNs) that might become operative before the induction of specific immune responses. Furthermore, we tested whether MxA protein induced in these cells in response to IFN or expressed constitutively in Vero or glioblastoma cells can confer resistance to RSV strain A2, as was shown before with PIV3 (Zhao et al., 1996) . We also tested whether other antiviral proteins produced by IFNs protect the Hep-2 cells that do not express MxA protein against RSV or PIV3. Finally, we investigated whether RSV A2 or PIV3 can affect each other during coinfections in the absence or presence of IFNs. In this report, we demonstrate that although RSV and PIV3 belong to the same Paramyxoviridae family, RSV A2 possesses replicative strategies resistant to the antiviral effects of type I IFNs and MxA. To our knowledge, this is the first report on the investigation of antiviral effects of MxA on RSV infection.
RESULTS

Effect of exogenously added type I IFNs on virus production by RSV A2 in A549 or MRC-5 cells
As shown in Fig. 1A , exogenously added IFN-␣ or -␤ exhibited only minor inhibitory effects on the yields of infectious RSV in A549 cells. Even at high doses of IFNs (5000-10,000 U/ml), virus yields were decreased to only about 5-10% of the IFN-untreated controls. In contrast, under the same conditions, yields of infectious PIV3 were reduced significantly. At 10,000 U/ml dose of IFN-␣ or -␤, PIV3 yield was decreased to 0.1-0.01% of the untreated controls. Similar results were obtained using MRC-5 cells with both IFN-␣ -␤ ( Fig. 1B) . Compared with A549 cells, in MRC-5 cells the antiviral effects at lower doses of IFNs appeared to be to slightly less pronounced against PIV3, suggesting inherent cellular differences in responding to IFN treatment.
We also compared RSV A2 sensitivity with the antiviral effects of 1000 U/ml either IFN-␣ or -␤ in the cells (1) treated for 20 h before the 2-h virus absorption and infection, (2) treated after the 2-h absorption and continued throughout thereafter, or (3) treated for 20 h before as well as during the first 24 h or the entire infection period. Results (data not shown) indicated that treatments 1 and 3 resulted in 10-to 20-fold reduction in virus yields compared with the untreated controls. Samples from treatment 2 resulted in virus yields essentially the same as the untreated controls. These results suggested that even the slight antiviral activity (10-to 20-fold reduction in yield) due to either of the IFNs observed against RSV A2 was seen only if the cells were pretreated with IFN-␣ or -␤ before infection but not after the infection was initiated.
Effect of virus load on the antiviral activity of IFN-␣ in A549 cells
We next tested whether the amount of virus load determines the extent of its sensitivity to a fixed amount of IFN-␣. A549 cells were pretreated with 1000 U/ml of IFN-␣ and infected by either RSV A2 or PIV3 at 3 separate multiplicities of infection (m.o.i.) (i.e., 0.01, 0.1, or 1.0 PFU/ cell) and virus yields in the supernatants at 40 h postinfection (p.i.) were determined. Table 1 shows the representative data from a typical experiment. Even at the lowest virus RSV input (0.01 PFU/cell), virus yield in the IFN-treated sample decreased only to about 20-fold (1.3 log 10 PFU/ml decrease) compared with the untreated sample. A 10-fold increase in the virus inoculum (0.1 PFU/cell) also resulted in a similar reduction (19-fold) in virus yield. A further increase in virus inoculum (1.0 PFU/ cell) resulted in further increase in virus yield when treated with IFN (only 8.5-fold reduction). These results indicate that RSV A2, in general, is very resistant to the antiviral activity of a given amount of IFN-␣ regardless of the virus load. In other words, 1000 U/ml IFN-␣ could not significantly protect 1 ϫ 10 6 A549 cells even when challenged with low doses of RSV A2.
In contrast, PIV3 was found to be extremely sensitive to IFN-␣; at the lowest virus load tested (0.01 PFU/cell), virus yield in the IFN-treated sample is decreased by as much as about 158,000-fold (5.2 log 10 PFU) compared with untreated sample. A 10-fold increase in the virus inoculum (0.1 PFU/cell) resulted in a 10,000-fold (4 log 10 PFU) decrease in virus yield in IFN-treated sample. At the highest m.o.i. tested (1 PFU/cell), the virus yield in IFNtreated sample was decreased by only about 472-fold (2.7 log 10 PFU) compared with the untreated sample. Even this level of reduction in PIV3 virus yield is significant compared with RSV A2 under similar conditions (compare 472-fold with 8.5-fold reduction, respectively). These results suggest that IFN-␣ may be extremely effective against low amounts of PIV3 virus but that a high virus load can overcome the antiviral activity of a given amount of IFN-␣.
Effect of IFN inducers on RSV A2 virus yields in A549 cells
To rule out the possibility that IFN induced from within the same cells somehow would be more effective than exogenously added IFN, we treated A549 cells with known IFN inducers such as poly(IC) alone (simple induction) or in combination with DEAE-dextran (super induction) and evaluated their effects on the infectious virus production by either RSV A2 or PIV3. As shown in Fig. 2A , the treatment of A549 cells with increasing amounts of poly(IC) in the absence or presence of DEAE-dextran did not inhibit infectious RSV A2 virus production significantly (a decrease to 5-10% of the untreated controls). Under the same conditions, infectious PIV3 virus yield is drastically FIG. 1. Infectious virus yields of RSV A2 and PIV3 after pretreatment of A549 (A) and MRC-5 (B) cells with 0-10,000 U/ml IFN-␣ or -␤ for 20 h, followed by infection with the respective viruses at an m.o.i. of 0.1 PFU/cell. The cells were harvested 40 h p.i., and the viruses in the supernatants were titrated on Hep-2 cells. Infectious virus yield for each virus in IFN-treated samples at each dose was calculated as a percentage of the total virus yield, in PFU/ml, obtained in mock-treated control samples. Each point shown represents the mean percent virus yield value obtained from at least three separate experiments, and the bars show the standard deviation. decreased (to 0.01-0.001% of the untreated controls). Figure 2B shows that RSV-specific protein synthesis was not affected by poly(IC) treatment. We directly measured the amount of IFNs produced in these and other experiments (data not shown) and found that poly(IC) alone induced 100 U/ml and that poly(IC) plus DEAE-dextran induced 1000-2000 U/ml of antiviral activity, respectively, in A549 cells. These results, therefore, suggested that in A549 cells, (1) poly(IC) either alone or in combination with DEAE-dextran induced IFNs with antiviral activity, (2) these IFNs are effective against PIV3, and (3) RSV A2 infection somehow was resistant to the antiviral effects of these internally induced IFNs also.
Effects of type I IFNs on induction of antiviral MxA and translation of RSV proteins
We tested whether (1) antiviral MxA protein is expressed in MRC-5 and A549 cells in response to type I IFNs and (2) type I IFNs have any effect on RSV A2specific protein synthesis. In these experiments, MRC-5 cells were either mock treated or treated with 100, 500, or 1000 U/ml IFN-␣ or -␤ for 20 h and then infected with RSV FIG. 2. Effects of poly(IC) alone (simple induction) or in combination with DEAE-dextran (super induction) on infectious virus yields of (A) RSV A2 or PIV3 and (B) RSV A2 viral protein expression. A549 cells were pretreated with 0-100 g/ml poly(IC) alone or mixed with 100 g/ml of DEAE-dextran for 20 h followed by infection at an m.o.i. of 0.1 PFU/cell for 40 h. Supernatant samples were harvested, collected, and titrated on Hep-2 cells, and infectious virus yields (A) were calculated as described. Data represent the mean percent virus yield value obtained from at least three separate experiments, and the bars show the standard deviation. Western blot analysis (B) of total cellular proteins using RSV-specific rabbit polyclonal antibodies (at 1:1000 dilution) shows that viral protein synthesis was not affected by treating the cells with increasing amounts of poly(IC) (lanes 2-6) before infection.
A2. At 20 h p.i., cells were harvested and total cell lysates were prepared, separated by SDS-PAGE, and analyzed by Western blots using MxA-and RSV-specific antisera. MxA protein was found to be produced in a dose-specific response to either IFN-␣ or -␤, respectively ( Fig. 3 , top, lanes 1-8). This result clearly indicates that MRC-5 cells were able to respond to type I IFNs and that antiviral proteins were made. However, RSV A2 viral protein synthesis did not decrease significantly under these conditions. As shown in Fig. 3 , bottom, the levels of RSVspecific proteins were identical in mock-treated (lane 2) and IFN-treated (lanes 3-8) samples. Similar results obtained with A549 cells (data not shown) indicated that the observed resistance of RSV A2 to type I IFNs is not cell type specific or due to a general defect in the IFN pathway in these cells.
Production of infectious RSV A2 in MxA protein expressing cell lines
We next directly tested whether cells stably expressing human MxA protein are resistant to infection by RSV A2 or PIV3. We used two separate cell lines, of human or simian origin transfected with a human MxA gene, that constitutively expresses MxA protein in the presence of the drug G418 (Schneider-Schaulies et al., 1994; Haller et al., 1993; Zhao et al., 1996; Kanerva et al., 1996; Frese et al., 1996) . In these cells, infectious RSV or PIV3 yields were compared at two virus loads (0.1 or 1.0 PFU/cell), and cell supernatants were harvested at 24, 48, 72, or 96 h p.i. in both cases to compare them at different stages after multiple rounds of replication. Figure 4A shows the expression of MxA protein in stably transfected cells VA-9 and U-87-H4 and lack of its expression in the parent cells VN-5 and U-87-CL4. As seen in Fig. 4A , slightly less MxA was produced in U-87-H4 compared with VA-9 cells. The infectious virus yields of RSV A2 and PIV3 in these cell lines at 0.1 and 1.0 PFU/cell after 24 h of infection are shown in Fig. 4B . MxA-expressing cells (VA-9 and H-4) were not resistant to the infection by RSV A2 compared with the cells lacking the MxA protein (VN-5 and H-4). This is evident by the similar amounts of infectious virus produced by RSV A2 in both MxA-expressing and -nonexpressing cells. This result was consistently observed regardless of the dose of the virus inoculum (0.1 and 1.0 PFU/cell) or duration of total infection [i.e., 24 h ( Fig. 4B ), 48 h, 72 h, or 96 h (data not shown)]. In contrast, multiplication of PIV3 was reduced by 100-to 500-fold in MxA-expressing cells, especially at the lower doses of inoculum and when the infection was carried out for 24 h. At higher m.o.i. or when infection was carried out for longer periods of time (i.e., up to 72 or 96 h), the amount of infectious PIV3 produced in MxA-expressing cells was not significantly different from that obtained in MxA-nonexpressing cells (data not shown).
Effect of type I IFNs on RSV A2 and PIV3 in Hep-2 cells that do not express MxA protein
IFNs induce a number of antiviral proteins in host cells in addition to MxA protein (Staheli, 1990; Samuel, 1991) . We therefore investigated the antiviral effects of type I IFNs against both RSV A2 and PIV3 in Hep-2 cells, which do not express MxA protein but may have other IFN-induced antiviral proteins. The experiments were carried out under identical conditions of IFN treatments in either Hep-2 or A549 cells. Figure 5A shows the Western blot analysis of MxA expression in IFN-treated A549 cells and its absence in IFN-treated One blot was reacted with rabbit polyclonal antibody against human MxA, and a duplicate blot was reacted with rabbit polyclonal antibody against RSV A2 (both at 1:1000 dilution), as described in the text. The positions and molecular masses (M) of marker proteins (prestained markers, BioRad) are indicated to the left; MxA protein and RSV nucleocapsid protein N and phosphoprotein P are indicated to the right.
Hep-2 cells using highly specific anti-MxA antibodies from which cross-reacting antibodies against MxB were removed. The use of these specific antibodies was necessary because IFN can induce MxB in Hep-2 cells . Figure 5B shows results of the antiviral effects of IFN-␣ on RSV A2 or PIV3 in Hep-2 or A549 cells from a representative experiment. The virus yield of RSV A2 in either cell line was greater than 10% of the control, suggesting that RSV A2 was also resistant to other IFN-induced antiviral proteins. As expected, PIV3 yield was reduced to 0.5-0.1% of the untreated control in A549 cells that express MxA protein. In Hep-2 cells that do not produce MxA protein, PIV3 yield was less inhibited (5% of the untreated controls) but still more sensitive to IFN than RSV A2. Therefore, in cells that do not express MxA, antiviral effects of IFN-␣ may be mediated by other IFNinduced antiviral proteins in inhibiting PIV3 multiplica-tion, although the inhibition was not as effective as that in the cells that express MxA.
Effect of IFN-resistant RSV A2 on IFN-sensitive PIV3 during coinfection
The observed resistance of RSV A2 to the effects of type I IFNs may be due to disruption of the cellular antiviral state by RSV infection such that RSV A2 replication and production of infectious progeny are not inhibited. This disruption may be mediated by factors secreted into the culture medium by RSV-infected cells or induced within the RSV-infected cells. To test the possibility that RSV disrupted the cellular antiviral responses, we sought to determine the consequences of coinfection with both IFN-resistant RSV and IFN-sensitive PIV3 on PIV3 replication in IFN-treated cells. If RSV disrupted the cellular antiviral responses, then PIV3 replication should be spared from antiviral effects of IFNs. The results of these experiments are described in Fig. 6 and Table 2 . Figures 6A-6D , left, show the data from samples in the absence of IFNs, and Figs. 6F-6I show data from samples treated with 1000 U/ml IFN-␣. When RSV-or PIV3infected monolayers were tested with virus-specific monoclonal antibodies (MAbs), very clear cytopathic effects (CPEs) characteristic of RSV and PIV3, respectively, were seen (Figs. 6A and 6B). This indicates ongoing infection and replication of RSV or PIV3 in these monolayers in the absence of externally added IFN-␣. In these and other experiments, PIV3-specific large CPEs developed much faster (within 48 h) and are very distinct and visible under light microscope without the aid of any chromogenic reagents. Therefore, the use of PIV3-specific MAbs provides additional supporting evidence for the PIV3-specificity of the observed CPEs (Fig. 6B) . Under similar conditions, RSV A2 takes much longer to show clear CPEs (5-8 days) and the need for RSVspecific MAbs is warranted to identify, as well as to establish the specificity of the small RSV-specific CPEs in the monolayers (Fig. 6A) . Figure 6C shows the coinfected culture in the absence of IFN-␣ and the cells were treated with RSV MAbs; both RSV-specific small CPEs (arrowheads) and large, clear, unstained CPEs characteristic of PIV3 (boxed area) are separate, indicating the cells that were singly infected with either RSV or PIV3. In addition, some large, rounded PIV3 like CPEs but stained positive with RSV-specific MAbs are seen (arrows), suggesting that they were doubly infected with both RSV and PIV3. A PIV3-specific CPE that was devoid of stain on one side but stained positive for RSV proteins on another FIG. 6. Indirect immunocytochemistry on A549 cell monolayers showing the effects of IFN-␣ on RSV A2 and PIV3 in single or coinfections. A549 cells (1 ϫ 10 6 ) were either mock-treated or treated with 1000 U/ml IFN-␣ for 20 h followed by 2-h adsorption with RSV A2 (2500 PFU) or PIV3 (500 PFU) alone or together in 1-ml volume. Infected monolayers were incubated under 1% methyl cellulose overlay medium for 48 h at 37°C. When side (highlighted asterisk) is also seen. Figure 6D shows a duplicate monolayer coinfected with RSV A2 and PIV3 but treated with PIV3-specific MAbs where large, rounded PIV3-specific CPEs stained positive for PIV3 proteins are seen. Note the CPE indicated by the arrow in Fig. 6D that reacted positive with PIV3 MAb is very similar to the doubly infected CPE shown by the arrow in Fig. 6C . However, no small RSV-specific CPEs were seen in these coinfected cells.
When treated with IFN-␣, RSV-infected cells still developed characteristic CPEs, although the numbers were slightly reduced ( Fig. 6F and Table 2 ), but in IFN-treated PIV3-infected monolayer, all the distinctive PIV3-specific CPEs were totally absent as expected. Occasionally, in only some experiments, up to five lightly stained individual cells (of 1 ϫ 10 6 cells) were seen (Fig. 6G ). Except for this very light staining indicating a positive reaction for PIV3 proteins, these cells do not resemble typical PIV3specific CPEs. Because they were not observed consistently in most experiments, they were not considered to be very significant. This is in stark contrast to the hundreds of PIV3-specific CPEs seen in IFN-untreated cells (Fig. 6B) . When IFN-treated, coinfected cells were tested with RSV MAbs, the small RSV-specific CPEs were observed ( Fig. 6H ) similar to those observed in single RSV infection experiments (Fig. 6F ). However, there were no PIV3-specific CPEs in the monolayer. Even the PIV3-like CPEs that stained positive with RSV MAbs in the absence of IFN-␣ (Fig. 6C, arrows) were totally absent in IFN-treated coinfections (Fig. 6H) . These results suggest that coinfection with RSV did not prevent the IFN-mediated inhibition of PIV3 replication and CPE formation. This is further confirmed in duplicate sets of IFN-treated, coinfected monolayers that were tested with PIV3-specific MAbs where PIV3-specific CPEs completely disappeared and the single, lightly stained cell was seen only once in six to eight separate experiments (Fig. 6I) . A comparison of the data in Fig. 6B with Fig. 6G and that in Fig. 6D with Fig. 6I indicates that IFN-␣ was able to inhibit PIV3 replication and CPE formation in both single infections and coinfections, respectively. Even if when the infection time was further extended to 72 h, allowing the slow-growing plaques to be detected, no PIV3-specific or "hybrid" (doubly infected) CPEs were observed. Table 2 presents the quantification of the above results. In the absence of IFN, the total number of RSV-PIV-3-specific CPEs were visible, cells were fixed, blocked in 5% (w/v) nonfat dry milk in TTBS, and treated overnight with either RSV-(G and Note. Cumulative data from three separate experiments; in each experiment, each treatment was done in duplicate or triplicate wells. a RSV-specific small CPEs (Fig. 6A) ; data represent mean Ϯ S.D. b PIV3-specific large CPEs (Fig. 6B) ; data represent Mean Ϯ S.D. c PIV3-specific large CPEs but stained positive with RSV-specific MAb (Fig. 6C, arrow specific CPEs in both single (treatment 1) and coinfections (treatment 3) were almost the same, suggesting that infection by PIV3 did not preclude the infection and replication of RSV. Similarly, the number of PIV3-specific CPEs in single (treatment 2) and coinfections (treatment 4) were almost the same, indicating that infection by RSV did not prevent the infection by PIV3. The presence of "hybrid" CPEs also indicates that these viral infections were not mutually exclusive. With 1000 U/ml IFN-␣, in both single and coinfections, there was only about a 4-to 5-fold decrease in RSV-specific CPEs compared with untreated controls. Hence, RSV was not very sensitive to the added IFN, and even in coinfections, the presence of PIV3 did not make RSV more sensitive to the antiviral effects of IFN-␣. The number of PIV3-like CPEs that stained positive with RSV A2 MAb (doubly infected CPEs) in coinfections (treatment 3) represents about 10% of the total RSV CPEs that were totally absent in IFN-treated monolayers. PIV3 was acutely sensitive to IFN-␣, in both single or coinfections, and no PIV3-specific CPEs were seen in IFN-␣-treated cells. This demonstrates that the presence of IFN-resistant RSV A2 in the same cell did not prevent the IFN-mediated inhibition of PIV3 growth and multiplication. Similar to mock-treated cell monolayers, it is possible for some cells (about 10%) to be infected by both viruses even in the IFN-treated monolayers because IFN-␣ does not prevent infection of the cells by PIV3 but acts at a later stage of infection (Zhao et al., 1996) . However in IFN-treated coinfected monolayers, no doubly infected cells (PIV3-specific CPEs and positive for RSV antigen) were seen, probably because PIV3 replication continued to be inhibited by a cellular antiviral mechanism that remains active even in the presence of RSV replication. Merolla et al., 1995) . In this study, we demonstrated only a minor reduction in viral yield (Fig. 1) and a lack of reduction in viral protein synthesis (Fig. 3) when RSV A2 replicated in IFN-treated human lung fibroblasts (MRC-5) or the human lung alveolar epithelial cell line (A549) compared with IFN-untreated cells. This interpretation was based on the fact that many viruses considered highly sensitive to IFN (e.g., VSV, HSV, PIV3) generally exhibited at least a 100-fold decrease in their yields of infectious virus (Belkowski and Sen, 1987; Zerial et al., 1982; Zhao et al., 1996) . Earlier studies considered a 50% (2-fold) reduction in RSV yield to be significant (Gardner et al., 1970; Hall et al., 1978) . Studies that reported RSV sensitivity to 5 or 2.5 U of human leukocyte IFN (1.5 log 10 reduction in titter) used the Long strain of RSV, tested in primary Patas monkey kidney cells (Gardner et al., 1970) . In our hands, the Long strain was not more sensitive than RSV A2 to any dose (10-10,000 U/ml) of IFN-␣ or -␤ when tested in A549 cells (P. L. Atreya, unpublished data) . This lack of inhibition of RSV A2 in response to IFNs was not dependent on the source of IFN, either externally added (Fig. 1) or internally induced (Fig. 2) by IFN inducers such as poly(IC). Under these conditions, antiviral protein MxA was induced and expressed in a dose-dependent manner in response to both IFN-␣ or -␤, indicating that at least this pathway of the antiviral state was clearly established in both A549 and MRC-5 cells. Furthermore, this established antiviral state appears functional because infectious virus yields of PIV3 were drastically reduced under these conditions, as was reported earlier by Zhao et al. (1996) .
DISCUSSION
RSV replicates in both MRC-5 and A549 cells (McKay
In preliminary experiments, we tested whether the amounts of (10-10,000 U/ml) various IFNs (␣ or ␤) used in these experiments were toxic to A549, MRC-5, or Hep-2 cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) cytotoxicity assays. Results of these experiments indicated that even at the highest amounts of IFN (i.e., 10,000 U/ml), IFN-treated cells were metabolically as viable as the untreated cells (within 10-15% of the control; data not shown). Hence any inhibitory effects observed in our experiments were not due to nonspecific effects of cellular toxicity induced by IFNs.
Even the slight reduction in virus yields of RSV A2 in IFN-treated samples was observed only if IFN treatment occurred before infection but not after the infection was initiated. The reductions in virus yields of samples subjected to a combination of preinfection and p.i. IFN treatment were essentially the same as the reduction in virus yields of samples, only pretreated with IFNs. Based on this, we cannot rule out the possibility that the initial infection of RSV may have been slightly inhibited in the cells treated with IFN before infection. Once RSV infection was initiated, IFNs did not seem have any effect on subsequent rounds of virus replication and burst size. Analysis of the effect of IFN on RSV infection described in Figs. 6A and 6F and Table 2 also seems to support this possibility. Here, the total number of RSV-infected cells was decreased sufficiently (ϳ5-fold) by pretreatment of the cells with IFN-␣ (Fig. 6F) to account for the reduction in their titer. However, it remains to be determined how the initial infection of RSV A2, if at all, may be inhibited by pretreatment of the cells with IFN-␣.
We directly compared the sensitivity of PIV3 and RSV A2 to a given amount of IFN-␣ at three separate viral loads. This type of comparison is perhaps useful in determining the effective dose of IFNs against specific viruses. Our results (Table 1) show that IFN-␣ was extremely effective against a low dose of PIV3 but that at a higher PIV3 load, the antiviral activity of a given amount of IFN-␣ may become ineffective. This result indicates some sort of a direct, dose-dependent interaction between PIV3 viral components and IFN-induced antiviral factors that might become saturated at higher viral loads.
In contrast, even at a low virus dose, RSV seems relatively insensitive to the antiviral effects of IFN-␣. A 10-or 100-fold increase in virus loads did not significantly change the level of sensitivity to IFN any further, suggesting that there may not be a direct, dose-dependent interaction between viral components and IFN-induced antiviral factors.
Cells lacking MxA protein produced similar amounts of infectious virus yields of RSV A2 compared with cells that do express MxA (Fig. 4) , demonstrating that the expression of MxA did not affect RSV A2 replication. This was observed in two separate cell lines, of human or simian origin, indicating that the observed effects are specific to the virus rather than to the cell type. In contrast, in both types of MxA-expressing cells, 100-to 500-fold less infectious PIV3 was produced, suggesting that the presence of MxA inhibited PIV3 replication. However, with increasing virus loads as would be expected in extended incubation periods due to multiple rounds of infection, the protection offered to the cells by constitutively expressed MxA appeared to decrease. Previously, Zhao et al. (1996) Because many antiviral proteins are induced in response to IFN in addition to MxA (Staheli, 1990 , Samuel, 1991 , we tested whether in the absence of MxA other IFN-induced antiviral proteins can confer resistance to RSV or PIV3. We found that in IFN-treated Hep-2 cells that do not express MxA , although RSV infection was not significantly affected, PIV3 virus yields were still diminished, although to a lower extent, compared with the yields in IFN-treated A549 cells that express MxA protein (Fig. 5) . Hence, PIV3 replication may be independently inhibited by MxA and other IFNinduced antiviral proteins. However, cumulative effects of MxA and other antiviral proteins may be much more effective against PIV3. Our results lead to similar conclusions as those drawn by Zhao et al. (1996) , although they used the IFN-treated U-87 parent cell line to test the effects of other antiviral proteins against PIV3. Zhao et al. (1996) reported that in MxA-expressing cells, although PIV3 replication was decreased by more than 100-fold with concomitant viral RNA synthesis by 80%, primary viral transcription was not affected. In contrast, in the parent U-87 cell line, IFN-mediated inhibition occurred at the primary transcription of PIV3 replication. These data suggested that in addition to MxA, other IFN-inducible antiviral proteins are effective against PIV3 in both the cell lines.
We did not characterize the other IFN-responsive antiviral proteins induced in Hep-2 cells in this report. In addition to MxA, two other best-characterized antiviral mechanisms are known to exist in many cell types: (1) double-stranded (ds)RNA-dependent protein kinase R and (2) dsRNA-dependent 2Ј,5Ј-A activated RNase L. The former enzyme is known to mediate antiviral effects by inhibiting host cellular and viral protein synthesis through phosphorylation of the translation factor eIF2 and the latter enzyme by the dsRNA-induced breakdown of single-stranded viral and cellular RNA. Although we did not directly measure the activities of protein kinase R or RNase L enzymes in IFN-treated A549 cells, it is possible that RSV A2 replication also may be resistant to these antiviral mechanisms. Evidence for this suggestion comes from the observation that both RSV protein synthesis ( Fig. 3 ) and viral RNA levels (data not shown) were not significantly decreased by prior IFN treatment. Direct testing of these enzyme activities in IFN-treated, RSVinfected cells is needed to further verify these hypotheses.
Previously, it was shown that another IFN-resistant virus, human adenovirus Ad5, not only replicated efficiently in A549 cells in the presence of IFN-␣ but also prevented the IFN-mediated inhibition of VSV replication (Anderson and Fennie, 1987) . Adenovirus early region E1A-encoded product interferes with transcriptional signaling process of IFN, thus blocking the effects of IFN (Leonard and Sen, 1997) , and thereby blocks the cellular response that inhibits VSV replication. In the present study, we investigated whether IFN-resistant RSV A2 could offer similar protection to highly IFN-sensitive PIV3 when A549 cells were coinfected simultaneously with both viruses in the presence of IFN-␣. We hypothesized that if the apparent resistance of RSV A2 to IFN-␣ was due to the inactivation of IFN-induced antiviral state by RSV infection [either by induction of soluble factors released into the medium or within the RSV-infected cells by interfering with IFN-stimulated gene (ISG) expression], then PIV3 multiplication in the coinfected cell culture should also be spared from the antiviral effects of IFN-␣.
Our data ( Fig. 6 and Table 2 ) clearly demonstrate that although the number of RSV-infected cells were slightly decreased ( Fig. 6F ; probably due to the slight inhibition of initial infection), viral replication in IFN-treated, RSV A2-infected cells seemed to proceed normally as indicated by the RSV-specific CPEs similar to those observed in untreated cells. A similar number of RSV-infected cells were seen in IFN-treated, coinfected cultures (Fig. 6H) . The continued IFN-resistant replication of RSV A2 in the coculture did not, however, protect PIV3 from the antiviral effects of IFN-␣. One possibility is that the resistance of RSV A2 to IFN-␣ may not have been mediated by soluble factors released into the medium by RSV-infected cells. In addition, even within the same cells that are coinfected with both viruses, PIV3 was not spared from the inhibitory effects of IFN, suggesting that the established antiviral state was still functional and effective against PIV3.
RSV A2 infection may not be actively disrupting the antiviral ISG expression and their activity. We speculate that the apparent resistance of RSV A2 replication to IFN-␣ may be due to insensitivity of the viral polymerase to ISGs and antiviral proteins in the presence of a viral factor or factors rather than the active disruption of IFNstimulated antiviral state. There are at least three RSV proteins whose functions are not clearly defined and probably could have a role in protecting RSV replication from the antiviral host response. These proteins probably are absent during initial infection, making it somewhat vulnerable, but are produced once the infection is initiated and subsequent rounds of transcription and translation take place. We have recently shown that NS1, one of the RSV nonstructural proteins, has potent negative regulatory effects on viral replication and transcription in a RSV model minigenome system (Atreya et al., 1998) . NS2, another RSV nonstructural protein, seem to have similar inhibitory effects on viral polymerase in a minigenome system, but compared with NS1, much higher amounts of NS2 were needed for such inhibitory effects (P. Atreya and P. Collins, unpublished data) . A small hydrophobic protein of RSV is produced in RSV-infected cells that is also known to be present in the virions; the function of this protein also is not yet clearly defined. In addition, an internal open reading frame (ORF-2) of the M2 protein of RSV has been reported to have a role in inhibiting the RSV minigenome transcription and replication (Collins et al., 1996a) , but it may have other functions in vivo. Some of the recently described natural mutants or the recombinant RS viruses lacking the small hydrophobic and other viral proteins seemed to exhibit altered growth properties and plaque morphology compared with wild-type RSV A2 (Karron et al., 1997 , Bukreyev et al., 1997 , Teng and Collins, 1999 . Further investigation of such deletion mutants of RSV for their sensitivity to IFNs may indicate whether some of these viral proteins have a role in protecting viral replication from the antiviral effects of IFNs.
MATERIALS AND METHODS
Cell lines, viruses, IFNs, and antibodies
Human lung epithelial carcinoma cells (A549, ATCC, CCL-185), human lung fibroblast cells (MRC-5, ATCC, CCL-171), human epidermoid laryngeal carcinoma cells (HEp-2, ATCC, CCL-23), and PIV3 strain 243 (ATCC, VR-93) were purchased from American Type Culture Collection (Manassas, VA). Human IFN-␣ (I-2396) and -␤ (I-1640) were purchased from Sigma Chemical Co. (St. Louis, MO) and diluted further in E-MEM containing 1% FCS, 2 mM L-Gln, and antibiotic and antifungal supplements (1% GASP and 2.5 mg/ml amphotericin B; Quality Biologicals, MD) before treatment of the cells. Poly(IC) was from Pharmacia Biochemicals (Piscataway, NJ), and DEAE-dextran was from ICN Biochemicals (Costa Mesa, CA). All the cell lines were maintained in E-MEM with 10% FCS and the above-mentioned antibiotic and antifungal supplements. An initial inoculum of RSV A2 and a mouse monoclonal antibody against PIV3 hemagglutinin were provided by Dr. Judy Beeler (CBER, FDA). Both RSV and PIV3 stocks were prepared in Hep-2 cells and titrated in Hep-2 cells by plaque assay.
Vero cell clones expressing (VA-9) or not expressing human MxA protein (VN-5) and human glioblastoma cell clones expressing (U-87-H4) or not expressing human MxA protein (U-87-CL4) were described previously (Haller et al., 1993; Schneider-Schaulies et al., 1994; Zhao et al., 1996) . The guinea pig polyclonal antibodies highly specific for human MxA (antibodies cross-reacting with MxB were removed by adsorbing the MxA antibodies to fixed and permeabilized recombinant baculovirus-infected cells expressing human MxB; Melen et al., 1996) and mouse monoclonal antibodies against RSV N, P, G, and F were described previously (Garcia-Barreno et al., 1989; 1996) . Polyclonal antiserum against RSV proteins was prepared in New Zealand White rabbits at the Division of Veterinary Services (CBER, FDA). Glioblastoma cells expressing MxA were maintained in E-MEM containing 10% FCS and antibiotic and antifungal supplements as mentioned and 0.5 mg/ml G418 (GIBCO-BRL, Rockville, MD). Vero cells expressing Mx A were maintained in DMEM with 10% FCS and antibiotic and antifungal supplements as indicated and 1 mg/ml G418.
Determination of effects of IFNs or IFN inducers on virus yields
The effects of externally added IFN-␣ or -␤ (0-10,000 U/ml) on infectious RSV A2 and PIV3 were tested in 70-80% confluent monolayers of either A549 or MRC-5 cells in 6-well culture dishes. Approximately 1 ϫ 10 6 cells/well were pretreated with indicated doses of IFN for 20 h and then infected with either RSV A2 or PIV3 at 0.1 PFU/cell m.o.i. except where indicated otherwise.
To analyze the effects of endogenously produced IFNs, cells were pretreated for 20 h with IFN inducers such as poly(IC) alone (0-100 g/ml) or in combination with DEAE-dextran (100 g/ml) and then infected with either RSV or PIV3 at 0.1 PFU/cell. Virus was adsorbed to the cells for 2 h, the inoculum was removed, and monolayers were washed twice with E-MEM containing 1% FCS and other antibiotic and antifungal supplements. Infection was carried out in the same medium for 40 h, and cells were harvested. The supernatants were collected and frozen immediately on dry ice and subsequently at Ϫ70°C until further analysis. The media supernatants collected from RSV A2-infected cultures were mixed with 1/20 volume of 2 M HEPES, pH 7.4, containing 2 M MgSO 4 as the stabilizer before freezing on dry ice.
The effects of stably expressed human MxA protein on infectious virus yields of RSV A2 or PIV3 were determined in either U-87-H4 (glioblastoma origin) or VA-9 (Vero or monkey kidney origin) cells in 75-cm 2 flasks. U-87-CL4 and VN-5 cells that lack MxA gene expression served as controls. Cells were adsorbed for 2 h with RSV A2 or PIV3 at an m.o.i. of 0.1 or 1.0 PFU/cell. At 24, 48, 72, or 96 h p.i., the media supernatants from duplicate flasks were collected and stored frozen until further analysis by plaque assay.
The effects of type I IFNs on RSV A2 in A549 cells that express MxA or in Hep-2 cells that do not express MxA in response to IFNs were investigated by pretreatment of the cells for 20 h with 0-5000 U/ml IFN-␣ or -␤, followed by infection and harvesting of the supernatants at 40 h p.i.
Determination of infectious virus yields by plaque assay
Briefly, Hep-2 cell monolayers (48 h after plating) were adsorbed for 1 h with a series of 10-fold dilutions of either RSV or PIV3 inoculum, and the infected monolayers were left for 5-8 days under 1% methyl cellulose overlay (in E-MEM with 1% FCS and antibiotic and antifungal supplements) until plaques become visible. The cell monolayers were stained with 0.1% crystal violet in 0.5% formaldehyde and 150 mM NaCl. The stained monolayers were washed and air-dried, and clear plaques were counted manually under light microscope. The infectious virus yields of the IFN-treated samples were determined as (number of plaques/ml of culture supernatant obtained from IFN-treated samples)/(number of the plaques/ml of culture supernatant obtained from untreated samples) ϫ 100.
MTT cytotoxicity assay
The effect of IFNs on the viability of the cell monolayers was determined using MTT based in vitro toxicology kit (Sigma Chemical Co.). Duplicate sets of cell monolayers were used for each IFN dose tested. In this system, the mitochondrial dehydrogenase enzymes of living cells cleave the tetrazolium ring of the yellow MTT to form purple formazan crystals, which are insoluble in aqueous solutions (Edmondson et al., 1988) . The crystals were dissolved in acidified isopropanol, and the absorbance of resulting purple solution was spectrophotometrically measured at 690 nm. An increase or decrease in the viable cell number results in a concomitant change in the amount of formazan formed, indicating the degree of cytotoxicity caused by the indicated dose of IFNs.
Western immunoblot analysis of human MxA and RSV viral proteins A549 or MRC-5 cells were induced with IFN-␣ or -␤ (0-1000 U/ml) or with poly(IC) with or without DEAEdextran for 20 h and then infected with RSV A2. About 20 h p.i., cells were harvested by separating the culture supernatants from cell pellets. Cell pellets were lysed in the sample buffer (NOVEX) and analyzed by SDS-PAGE for separating of intracellular MxA and viral proteins. Typically about 20 g of total cell protein lysate was separated on 4-20% gradient gels (NOVEX) under reducing conditions and transferred to an Optitran-supported nitrocellulose membrane (Schleicher and Schuell, NH) for Western blot analysis. Duplicate membrane blots were blocked with a blocking buffer (5% nonfat milk in TTBS that contains 0.01 M Tris-Cl, pH 7.5, 0.15 M NaCl, and 0.02% Tween 20) and incubated with polyclonal rabbit antisera (1:1000 dilution) or guinea pig antisera (1:100 dilution) against human MxA or against RSV (made in rabbit, at 1:1000 dilution) prepared in the blocking buffer for 18 h. The membranes were washed three times with TTBS and incubated further for 2 h in the blocking buffer containing either goat anti-rabbit or antiguinea pig IgG alkaline phosphatase conjugate (1 g/ ml). After three additional washes in TBS (TTBS minus Tween 20), the blots were treated with alkaline color development solution containing nitroblue tetrazolium and 4-bromo-2-chloro-indoylphosphate (Promega, WI) according to the supplier's protocols.
Coinfection of A549 cells with RSV and PIV3 followed by indirect immunocytochemistry
Briefly, A549 cells (1 ϫ 10 6 ) were either mock or pretreated with 1000 U/ml IFN-␣ for 20 h followed by infection for 2 h with (1) no virus, (2) 2500 PFU of RSV A2, (3) 500 PFU of PIV3, or (4) a combination of 2500 PFU of RSV and 500 PFU of PIV3. In preliminary experiments, RSV and PIV3 at the above-mentioned doses produced wellseparated, distinct CPEs that may be counted manually under the microscope. In addition, a fivefold excess of RSV relative to PIV3 was used to enhance the chance of doubly infected cells in coinfections. After the absorption of virus, cell monolayers were washed, and plaque overlay medium (1% methyl cellulose in E-MEM with 1% FCS and antibiotic supplements) was added as done for plaque assays. Virus infection was allowed to take place for 48 h by which time PIV3-specific CPEs became clearly visible. The overlay was aspirated, and cell monolayers were fixed with cold acetone and methanol (1:1) mixture for 10 min. After three washes with TTBS for 10 min each, the fixed cell monolayers were blocked with blocking buffer for 3 h and treated for 20 h with either a pool of mouse MAbs against RSV G and F proteins (1:50 dilution) or PIV3 hemagglutinin (1:1000). Subsequently, the cell monolayers were washed and incubated with the secondary antibody (goat anti-mouse IgG conjugated to horseradish peroxidase; KPL) at 1:1000 dilution for 2 h, and bound antibodies were stained and detected by SigmaSTAT HRP diaminobenzoate color-developing substrate (Sigma Chemical Co.). Stained RSV-or PIV3-specific CPEs were counted under Zeiss Stemi SV 46 in-verted light microscope and photographed under Olympus BX40 camera at 40ϫ magnification.
Preliminary experiments demonstrated that RSV-and PIV3-specific MAbs did not react with mock-infected cell monolayers, nor did these MAbs exhibit cross-reactivity with either RSV A2 or PIV3.
